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Inflammation is the immune system’s response to infectious
or noninfectious sources of danger. Danger recognition is
facilitated by various innate immune receptor families
including the Toll-like receptors (TLRs), which detect danger
signals in extracellular and intracellular compartments. It is
an evolving concept that renal damage triggers intrarenal
inflammation by immune recognition of molecules that are
being released by dying cells. Such danger-associated
molecules act as immunostimulatory agonists to TLRs and
other innate immune receptors and induce cytokine and
chemokine secretion, leukocyte recruitment, and tissue
remodeling. As a new entry to this concept, autophagy
allows stressed cells to reduce intracellular microorganisms,
protein aggregates, and cellular organelles by moving and
subsequently digesting them in autophagolysosomes. Within
the autophagolysosome, endogenous molecules and danger-
associated molecules may be presented to TLRs or loaded
onto the major histocompatibility complex and presented as
autoantigens. Here we discuss the current evidence for the
danger signaling concept in autoimmune kidney injury and
propose that autophagy-related processing of self-proteins
provides a source of immunostimulatory molecules and
autoantigens. A better understanding of danger signaling
should enable us to unravel yet unknown triggers for renal
immunopathology and progressive kidney disease.
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The integrity and survival of multicellular organisms depends
on the initiation of an immediate host defense against
infectious agents.1 Immediate pathogen recognition is
guaranteed by innate pathogen recognition receptors, which
can either activate complement-mediated killing or the
activation of parenchymal and immune cells to produce
cytokines and other mediators of inflammation designed to
contain the infection (Table 1). Although most receptors are
surprisingly specific for chemically defined pathogen-asso-
ciated molecular patterns (PAMPs), the sum of the different
receptor classes covers the entire spectrum of pathogens.
Recently, it has been shown that endogenous molecules that
are generated during tissue injury and labeled as danger-
associated molecular pattern (DAMP) molecules, can also
activate pattern recognition receptors similarly to PAMPs,
thereby offering a novel understanding of sterile types of
inflammation (Table 2).2 DAMPs can originate from
intracellular sources or can be generated from extracellular
matrix degradation. As such DAMPs would normally not be
available for presentation to immune sensors (Figure 1).
However, DAMPs can be generated and released during cell
stress, apoptosis, or necrosis due to traumatic, ischemic,
toxic, or inflammatory tissue injuries. It is likely that DAMPs
function as danger signals and that DAMP-mediated immune
activation developed during evolution to aid danger control
and tissue repair. If such a process escapes the normal control
and/or suppression of an adaptive immune response to
endogenous molecules, the recognition of PAMP and DAMP
by receptors of the innate immune system could contribute
to an autoimmune response.
In this review we provide a conceptual outline by
discussing examples from the field of autoimmune kidney
disease: first, we introduce the concept that DAMP release
from dying or generation by stressed cells can induce renal
inflammation inside the kidney. Second, we discuss the
possibility, that during an initial renal cell immune injury
against foreign antigens, endogenous neoantigens may be
generated. This can result in a process of antigen spreading,
eventually provoking an autoimmune response contributing
to the progression of renal disease by humoral and cellular
immune mechanisms. Third, we discuss the concept of
molecular mimicry of endogenous nucleic acids with viral
nucleic acids with the potential of promoting lupus nephritis
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through Toll-like receptors (TLRs) at the systemic level.
Forth, we summarize data on the role of TLRs in mediating
infection-associated flares of immune complex glomerulone-
phritis both at the systemic and the tissue levels. Finally, we
discuss the potential role of autophagy in many of the above
processes and in the eventual development of autoimmunity.
DANGER-ASSOCIATED MOLECULAR PATTERNS CAN DRIVE
RENAL AUTOIMMUNE TISSUE INJURY
The triggering events for the loss of tolerance, for example,
against glomerular basement membrane (GBM) collagen
components in anti-GBM disease, neutrophil or lysosomal
lysosome-associated membrane protein 2 (LAMP2) antigens
in antineutrophil cytoplasmic antibody–associated vasculitis,
or chromatin in systemic lupus erythematosus (SLE), remain
complex and difficult to sort out in individual patients.
However, it is clear, that genetic and environmental factors
need to overcome several check points before autoreactive
lymphocyte clones are allowed to expand, so that rising
serum concentrations of the respective autoantibodies
become detectable by enzyme-linked immunosorbent assay.3
Although suspected for a long time, only recently has
evidence been provided for molecular mimicry between
infectious and endogenous antigens such as LAMP2 as a
trigger for pathogenic antibodies in causing pauci immune
glomerulonephritis.4 In addition, there is little doubt that
autoantibodies against the a3NC1 domain of collagen IV are
pathogenic in anti-GBM disease, because they bind to the
intrarenal autoantigen and cause in situ immune complex
formation, which activate FcgR and complement factors.5
This process usually leads to focal necrosis of the glomerular
tuft, histopathologically referred to as necrotizing glomer-
ulonephritis.6 Podocytes and parietal epithelia are activated
to proliferate leading to crescentic glomerulonephritis.7 Both
types of lesions involve the local production of chemokines,
which enhance the influx of antigen-specific T cells and
macrophages into the glomerular compartment or the
periglomerular space. Resident cells, as well as infiltrating
cells, also produce proinflammatory cytokines such as IL-12,
TNF-a, and interferon-g (IFN-g). These cytokines will drive
T-cell responses toward the Th1 phenotype and the resulting
cellular immune response. Such T-cell responses are usually
counterbalanced by regulatory T cells in secondary lymphoid
organs as well as at the tissue level. However, in experimental
anti-GBM disease CD4þCD25þ Foxp3þCD69-CD45RBlow
regulatory T cells were less potent in suppressing nephritis as
compared with regulatory T cells from nonnephritic mice.8
Crescentic glomerulonephritis has therefore been classified as
the renal manifestation of a Th1-like delayed type of
hypersensitivity reaction.9 Antineutrophil cytoplasmic anti-
body–associated vasculitis is associated with comparable
glomerular pathology, even though termed pauci-immune,
that is, few, if any, glomerular immune complex deposits can
be seen.6 In antineutrophil cytoplasmic antibody–associated
vasculitis neutrophils disrupt the endothelium in the
microvasculature, causing focal glomerular necrosis by a
combination of the release of toxic granule contents,
ischemia, and complement activation.6 The novel danger
signaling adds to these mechanisms and highlights the
proinflammatory role of dying cells.10 Although early phases
of apoptotic cell death with the rapid removal of apoptotic
bodies may avoid the release of intracellular DAMPs and a
subsequent inflammatory response, late apoptotic or necrotic
cells release the content into the extracellular space.2 Here
they can bind to pattern recognition receptors either directly
on the cell surface or, after endocytosis, in the endosomal
compartment of immune and nonimmune cells (Figure 1).
Furthermore, the local activation of matrix-degrading
Table 1 | Classes of innate and adaptive pattern recognition
molecules
Compartment
Innate recognition
molecules
Adaptive recognition
molecules
Secreted to
extracellular fluids
Pentraxins (CRP, SAP,
pentraxin-3)
IgA, IgM, IgG, IgE
Complement factors
Mannose-binding lectin
Cell surface Mannose receptor T-cell receptors
Scavenger receptors B-cell receptors (Ig)
Complement receptors Antigen-presenting
molecules
Fc receptors
Toll-like receptors
Dectins
Intracellular
endosomes
Toll-like receptors MHC I, MHC II
Intracellular cytosol RIG-like helicases
NOD-like receptors
Inflammasome-activating
molecules
Abbreviations: CRP, C-reactive protein; Ig, immunoglobulin; MHC, major histo-
compatibility complex; NOD, nucleotide-binding oligomerization domain;
RIG, retinoic-acid-inducible protein; SAP, serum amyloid P.
Table 2 | Endogenous molecules proposed to function as
DAMPs by activating TLRs or other receptors
DAMP Receptor
HMGB1 TLR2, TLR4, RAGE, RIG
Heat shock proteins TLR2, TLR4
Hyaluronates, biglycan TLR2, TLR4
Heparan sulfate TLR4
Fibrinogen TLR4
Defensins TLR4
U1snRNP-IgG TLR7 (FcR/BCR)
DNA-nucleosomes-IgG TLR9 (FcR/BCR)
Adenosine A1/A2A/A2B/A3
ATP P1/P2X/P2Y
S100 proteins RAGE
dsDNA AIM2 – IL-1R
Cathepsin-B NALP3 – IL-1R
Uric acid crystals NALP3 – IL-1R
Abbreviations: AIM, absent in melanoma; BCR, B-cell receptor; DAMP, damage-
associated molecular pattern; HMGB, high-mobility group B; Ig, immunoglobulin; IL,
interleukin; NALP, Nacht domain-leucine-rich repeat- and PYD-containing protein;
RAGE, receptor for advanced glycation end products; TLR, Toll-like receptor.
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enzymes around apoptotic and necrotic cells can generate
fragments of extracellular matrix, such as hyaluronates and
biglycans, which can serve as DAMPs.2
Many studies of the heterologous model of nephrotoxic
serum nephritis in mice lacking TLR2 or TLR4support the
role of DAMPs in glomerular disease. In these knockout mice
full-blown crescentic glomerulonephritis is prevented by
reduced activation of proinflammatory mediators in the
glomerular compartment.11,12 Some studies have reported
similar results by using the autologous serum nephritis in
TLR-deficient mice or by co-injecting TLR agonists during
the immunization phase.13,14 Furthermore, there is evidence
from chimeric mice that TLR2 on both intrinsic glomerular
cells and on leukocytes is involved in this process.12 The
interpretation of these studies must take into account that
TLR activation modulates the immunization phase and the
adaptive immune response, which affects kidney disease by
additional extrarenal mechanisms. Although the role of TLR2
and TLR4 in crescentic glomerulonephritis is consistent with
their role for sterile inflammation in postischemic acute renal
failure,15–17 a potential role of endogenous RNA in activating
TLR3 during crescentic glomerulonephritis is less likely, as
serum nephritis could be induced in mice deficient in TRIF,
the adapter protein required for TLR3 signaling.18 Necrotic
cells activate primary mouse mesangial cells preferentially
through TLR2/MyD88 rather than TLR3/TRIF, making
endogenous dsRNA as a relevant DAMP for TLR3 ligation
less likely.18 One may speculate that HMGB1, hyaluronic
acid, biglycan fragments, or fibrinogen function as endogen-
ous TLR2 and TLR4 agonists in glomerular cells, as shown
for fibrinogen activating TLR4 in podocytes.19 Although self-
RNA does not seem to trigger TLR3/TRIF signaling in anti-
GBM nephritis, nuclear HMGB proteins can exert their effect
as cofactors for RNA and DNA recognition through TLR7
and TLR9 as well as TLR-independent nucleic acid recogni-
tion pathways.20 Whether such a potential process contri-
butes to anti-GBM nephritis has not yet been formally
examined. However, this mechanism could serve as an
explanation for the intraglomerular induction of type I IFNs,
which promote glomerular inflammation in autologous
nephrotoxic serum nephritis.21 Thus, glomerular cell injury
and extracellular matrix modification have the potential to
activate innate immune responses through the release of
intracellular DAMPs, which can activate pattern recognition
receptors such as TLR2 and TLR4 on adjacent glomerular
immune and nonimmune cells. The nature of these
glomerular DAMPs remains to be defined in detail, but data
from other areas provide sufficient evidence for the danger-
signaling hypothesis as a whole.2,10
EPITOPE SPREADING AS A MECHANISM FOR AN IMMUNE
RESPONSE IN RENAL DISEASE
The role of T cells and specifically CD8þ T cells in
autoimmune-mediated glomerular and tubulointerstitial
disease has been discussed for decades.22 Lately, clear
experimental evidence for the significance and mechanisms
of T-cell involvement in glomerular and tubulointerstitial
disease has been forthcoming, as recently reviewed by Sung
and Bolton.22 This process may also link glomerular
pathology and proteinuria to progressive interstitial disease.
Subsequent to injury in the glomerulus or in the tubuloin-
terstitium neoantigens can be generated leading to epitope
spreading with generation of neoantigens, which are then
presented by dendritic cells to T cells either within the kidney
or in draining lymph nodes.23–26 Potentially, such neoanti-
gens could at the same time exert their effect as DAMPs, and
activate the innate immune response through TLRs on
mesangial, epithelial, interstitial, and endothelial cells as well
as on macrophages and dendritic cells. The combined
activation of an innate and adaptive immune response would
lead to a propagation and spreading of the disease from the
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Figure 1 | Immune recognition of extrinsic and intrinsic
dangers. Pathogens release pathogen-associated molecular
patterns (PAMPs) that activate antigen-presenting cells (APCs) and
nonimmune cells through pattern recognition receptors. The
maturation of, e.g., APC-like dendritic cells leads to antigen
presentation in the presence of costimulatory molecules that set
off adaptive immune responses involving clonal expansion of
antigen-specific T and B cells. Necrotic cells release intracellular
molecules that can activate the same classes of immune receptors
and thereby act as danger-associated molecular patterns (DAMPs).
This mechanism can explain sterile types of inflammation that
present clinically like infectious diseases such as a gout attack
(DAMP¼ uric acid crystal) or postischemic tissue inflammation. In
SLE nuclear particles containing immunostimulatory nucleic acids
function as adjuvant-like DAMPs in addition to their role as
autoantigens. Apoptotic cell death avoids DAMP release and
inappropriate immune activation. Vice versa, genetic defects in
apoptosis or the rapid clearance of apoptotic cells by phagocytes
predispose to chronic inflammatory autoimmune diseases such as
SLE because secondary necrosis of apoptotic cells causes DAMP
release.
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glomerulus to the tubular and interstitial compartment.
Recently, Macconi et al.27 showed, in a model of proteinuria
secondary to reduction in kidney mass, that filtered albumin
was partially processed by tubular epithelial cells and
subsequently by dendritic cells, resulting in major histocom-
patibility complex (MHC) I-mediated antigen presentation
to CD8þT cells in the regional lymph nodes. Cytotoxic
CD8þ T cells specific for renal antigens then propagated
renal damage. This mechanism provides a novel explanation
for the progression of renal diseases by autoimmune renal
injury. This concept is further supported by a study using a
transgenic mouse model with podocyte-specific expression of
a neoantigen.28 Thus, intrarenal epitope spreading involving
intrinsic renal cells, dendritic cells, and T cells could
contribute to an autoimmune type of kidney injury. The
potential roles of the innate immune system and TLRs in this
process, as well as the contribution of autolysosomal
processing of neoantigens, have not been examined as yet.
ENDOGENOUS NUCLEIC ACIDS DRIVE LUPUS NEPHRITIS BY
TRIGGERING ANTIVIRAL IMMUNITY
Lupus nephritis is characterized by a loss of tolerance and a
polyclonal autoimmune response against multiple nuclear
and chromatin-related autoantigens, which are ubiquitous,
albeit hidden inside cells. Hence, nuclear autoantigens reach
the extracellular space only when apoptotic cells are not
properly removed and undergo secondary necrosis. This
process will foster the formation of immune complexes
containing autoantibodies and nuclear autoantigens that
contain immunostimulatory nucleic acids.29 Circulating
immune complexes tend to deposit in glomeruli and activate
FcgR and complement, either along the inside or the outside
the filtration barrier as well as in the mesangium, causing a
spectrum of different histopathological manifestations.29
Especially, diffuse proliferative lupus nephritis is associated
with mixed macrophage, T-cell, and B-cell infiltrates due to
local expression of proinflammatory cytokines and chemo-
kines.
A new entry into the pathogenesis of lupus nephritis is the
concept that the immune dysregulation in SLE is largely
homologous to antiviral immunity. For example, transcrip-
tome profiles of peripheral blood monocytes from lupus
patients show a profound induction of type I IFN and IFN-
related genes, recalling a classical antiviral response pattern.30
Immune complexes containing nuclear lupus autoantigens
have the potential to activate TLR7 and TLR9 on plasma-
cytoid dendritic cells and B cells initiating a response
program comparable to that during viral infection.30,31 This
was shown for immune complexes containing chromatin or
hypomethylated CpG-DNA that activate TLR932 as well as for
immune complexes containing U1snRNP that activate
TLR7.33,34 In addition, nuclear HMGB proteins can function
as cofactors for RNA and DNA recognition through TLR-
dependent as well as -independent nucleic acid recognition
pathways.20 The same IFN signature was found by tran-
scriptome profiling of glomerular isolates of human renal
biopsies, which may originate from either glomerular
leukocytes or intrinsic renal cells.35 In fact, complexed RNA
or dsDNA can trigger the production of large amounts of
IFN-a and IFN-b as well as multiple IFN-dependent genes in
glomerular endothelial cells and mesangial cells.36–38 As
endothelial cells and mesangial cells lack TLR7 and TLR9,
these responses rather involve TLR-independent nucleic acid
recognition pathways.36,38 Nevertheless, self-RNA recognition
by TLR7 has a dominant role in mediating SLE disease
activity.31,39 TLR7 deficiency40,41 or TLR7 blockade42 pre-
vents proliferative lupus nephritis in mice by specifically
impairing the production of RNA autoantibodies. Further-
more, lupus nephritis becomes more severe when TLR7
signaling is enhanced, for example, by TLR7 gene duplica-
tion43 or by genetic elimination of TLR7 inhibitors such as
SIGIRR44 or TLR9.45 Hence, self-nucleic acid-induced
‘pseudoantiviral’ immunity translates into autoimmune
tissue damage. The functional importance of type I IFN
was, also shown by studies, that observed almost complete
suppression of lupus nephritis in mice deficient in the type I
IFN receptor.46–49 Can this concept be translated to human
lupus? Type I IFN expression levels are elevated in SLE
patients with active disease and dropped on immunosup-
pressive therapy.50,51 Furthermore, type I IFN cause ultra-
structural changes in lymphocytes and endothelial cells, that
is, the tubuloreticular structures.52 These have only been
observed in three cohorts of patients: (1) patients with viral
hepatitis treated with IFN-a;53 (2) in renal biopsies of
patients with HIVAN;54 (3) and in blood lymphocytes of SLE
patients.55 In lupus nephritis biopsies these structures are also
commonly noted in glomerular endothelial cells and are
referred to as ‘lupus inclusions’.56 Lupus inclusions seem to
represent a specific type of IFN-a-induced protein assembly
in the cytosol of cells. As such they do not only serve as a
diagnostic tool57 but also as a hint for the pathogenic role of
IFN induction in lupus immunopathology. RNA and DNA
lupus autoantigens have additional, adjuvant-like, immunos-
timulatory properties by binding to viral nucleic acid
recognition receptors comparable to viral particles. This
may explain the overlapping clinical presentations of viral
infection and SLE, and suggest a new pathogenic concept of
lupus nephritis.58
HOW INFECTIONS CAN TRIGGER FLARES OF AUTOIMMUNE
KIDNEY DISEASE
It is a common clinical observation that various infections
induce flares of lupus nephritis, of renal vasculitis, of IgA
nephritis, or of other forms of immune complex glomer-
ulonephritis. Recently, a direct molecular mimicry between a
pathogen-derived protein and a lysosome chaperone LAMP2
protein in endothelial cells was identified, and showed to
function as an autoantigen, thereby triggering a pauci
immune focal necrotizing glomerulonephritis.4 Molecular
mimicry had been discussed as a mechanism for vasculitis for
many years, but had never been clearly shown. Besides such
direct and specific activation of the immune system by
32 Kidney International (2010) 78, 29–37
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molecular mimicry, other potential mechanisms for infec-
tion-associated activation of the immune response and
resultant renal immunopathology exist. For example, pha-
gocytosis of infected apoptotic cells by dendritic cells triggers
the expansion of autoimmunity-related Th17 T cells, whereas
phagocytosis of noninfected apoptotic cells favors the
expansion of immunosuppressive regulatory T cells.59 During
systemic infection circulating PAMPs activate immune cells
and nonimmune cells throughout the body, which affects
immune responses at the systemic as well as at the local level.
For example, vascular leakage is a hallmark of sepsis or
noninfectious tissue injury, because PAMPs increase vascular
permeability by activating TLRs on vascular endothelial
cells.60,61 The same mechanism enhances proteinuria during
immune complex glomerulonephritis as shown for systemic
LPS exposure from Gram-negative bacteria11,62,63 or lipo-
protein from Gram-positive bacteria.63 These bacterial cell
wall components enhance the permeability of glomerular
endothelial cell and podocyte monolayers by activating
surface TLR2 and TLR4.63,64 Viral nucleic acid complexes
have a similar effect when they reach the intracellular cytosol
and activate cytosolic viral nucleic acid sensors.36 These
experimental findings may explain why endotoxinemia or
sepsis produces a mild and short-lasting proteinuria in
humans.65 Such PAMPs may produce stronger and longer-
lasting renal dysfunction in patients with preexisting
glomerular diseases and a preactivated and thereby hyperre-
sponsive glomerular endothelium.
In addition, other PAMPs can activate TLRs and other
receptors of the innate immune system on glomerular cells to
secrete proinflammatory cytokines such as IL-6 and TNF-a,
thereby enhancing glomerular inflammation.66–69 As men-
tioned earlier, viral nucleic acids may also trigger glomerular
expression of type I IFN, which adds to the proinflammatory
microenvironment.37,38 The PAMPs as well as the secreted
mediators also activate resident dendritic cells as well as the
leukocytic cell infiltrate, which is usually present in chronic
nephropathies.70 These activated intrinsic renal parenchymal
cells and intrarenal immune cells also produce proinflam-
matory chemokines such as MCP-1/CCL2, CCL5/RANTES,
and CXCL10/IP-10, which will foster additional leukocyte
recruitment and renal damage. The potential of TLR agonists
to trigger disease activity of murine lupus-like immune
complex glomerulonephritis was assessed in MRL(Fas)lpr
mice. Agonists for TLR2, TLR3, TLR4, TLR7, RIG-I, and
cytosolic DNA sensors had a similar potential to aggravate
glomerular inflammation (Table 3).63,71–74 The TLR9 agonist,
unmethylated CpG-DNA, which may derive from viruses or
bacteria, was unique in inducing crescentic glomerulone-
phritis and renal vasculitis in nephritic MRL(Fas)lpr mice,74
and was the only TLR agonist that could trigger the onset of
glomerulonephritis in young MRL(Fas)lpr mice that had not
yet developed SLE-like autoimmunity.75 The latter is
remarkable because most reports are consistent in that
TLR9 expression is restricted to extrarenal plasmacytoid
dendritic cells, macrophages, and B cells in healthy mice.76
Obviously, the activation of immune cells outside the kidney
contributes to the onset of renal disease. In fact, CpG-DNA
and—to a lower extent most other PAMPs—enhanced
immune complex disease by increasing serum cytokine levels,
autoantibody levels, and glomerular immune complex
deposits in MRL(Fas)lpr mice (Table 3). Only the TLR3
agonist dsRNA aggravated lupus nephritis by activating
mesangial cells rather than by affecting immune complex
disease.72 Thus circulating PAMPs will not only activate an
antigen-specific adaptive immune response, but will at the
same time serve as nonspecific adjuvants, thereby enhancing
the response of preexisting B- and T-cell clones fueling the
autoimmune diseases. In addition, circulating PAMPs can
activate renal parenchymal cells and intrarenal immune cells
to enhance renal inflammation.
AUTOPHAGY, A POTENTIAL LINK TO AUTOIMMUNITY
Autophagy may be an as-yet-underappreciated link between
the innate and adaptive immune responses and danger
signaling. Autophagy was initially recognized as a pathway to
salvage cellular proteins during stress, such as starvation, to
guarantee cell survival.77,78 As such, autophagy represents an
early step in the organism’s strategy to promote survival, that,
if it fails, will result in apoptosis or even necrosis. During the
previous years it has become ever more apparent that
autophagy is also broadly associated with many steps of
immune responses.79–81
Pathways of autophagy
All mammalian cells undergo constitutive autophagy to some
extent, that is, they engulf and digest endogenous cytosolic
proteins, membrane particles, or intracellular organelles.77
Table 3 | Effects of transiently exposing MRL(Fas)lpr mice with lupus-like immune complex glomerulonephiritis to various TLR
agonists
PRR Ligand TLR2 lipoprotein TLR3 dsRNA TLR4 LPS TLR7 ssRNA TLR9 CpG-DNA ?, DAI dsDNA RIG-I 3P-RNA
Mesangiolysis  +     
Proteinuria +++ + + + + + +
Macrophages + + ++ + ++ + +
Inflammation ++ ++ ++ ++ +++ ++ ++
Anti-dsDNA +  + + +++ + +
Glom. C3 +  + + ++ + +
Lymphoprol. +  + + +++ +++ 
Abbreviations: C3, complement factor 3; ds, double stranded; glom., glomerular; lymphoprol., lymphoproliferation; 3P-RNA, 50-triphosphate RNA; PRR, pattern recognition
receptor; ss, single stranded.
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During starvation macro-autophagy is initiated by dimin-
ished phosphatidylinositol-3 kinase (PI3K) activation due to
loss of growth factors. PI3K normally activates the mamma-
lian target of rapamycin. Decreased mammalian target of
rapamycin activity secondary to diminished PI3K activity
or inhibition of mammalian target of rapamycin by, for
example, rapamycin will induce autophagy,77 which may
account for beneficial or detrimental effects in the kidney.
The formation of macro-autophagosomes proceeds by
invagination of newly formed double membranes to form
intracellular vesicles. This involves a number of autophagy-
related gene (Atg) products.77 During the formation of the
autophagosome portions of the cytosol as well as entire
organelles, such as intracellular membrane vesicles or
mitochondria, can be engulfed. The autophagosome then
fuses with lysosomes, forming the autolysosome (Figure 2).
In chaperone-mediated autophagy specific cytosolic proteins
are recognized by chaperone complexes, containing compo-
nents of the heat shock cognate protein HSC70 and LAMPs,
enabling docking to lysosomes and transfer of the captured
proteins for lysosomal degradation (Figure 2). Within the
lumen of the autolysosome, membrane structures and
proteins are degraded by lysosomal proteases, which are
activated by the acid pH generated by proton pump ATPases
of autolysosomes.77
AUTOPHAGY AS PART OF THE IMMUNE RESPONSE
In dendritic cells macro-autophagy and chaperone-mediated
autophagy can deliver both foreign and self-proteins to
autolysosomes, where they are processed and may eventually
come in contact with and bind to MHC class II in a
specialized compartment.82 In support of this concept is the
observation that more than 50% of autophagosomes merge
and colocalize with the MHC II loading compartment.83
Initial evidence for macro-autophagy also contributing to
MHC class I cross-presentation has been provided for tumor
antigens84,85 as well as for intracellular pathogens.86–90 Within
the autolysosomes pathogens can interact with membrane-
bound and cytosolic receptors of the innate immune system,
which reside in endosomal compartments (such as TLR3, -4,
-7, -9). Furthermore, cytosolic receptors such as retinoic
acid-inducible gene I (RIG-I), such as helicase receptors, and
other cytosolic receptors for RNA and DNA and NOD
receptors can interact with components of autophagy.86,91–93
Potentially, autophagy pathways may also deliver DAMPs,
generated by stressed or dying cells, to innate immune
receptors, such as TLRs present in autolysosomes.20,94–96
However, activation of a number of these receptors can in
turn enhance autophagy thereby further propagating the
process.80,92,97 The activation of receptors of the innate
immune system would then result in a proinflammatory
response as described above. Thereby, autophagy will
establish a connection between innate and adaptive immune
responses by delivering either infectious agents or modified
self-proteins and/or DNA or RNA to autolysosomes for
processing as foreign or self-antigens.
Autophagy also influences B- and T-cell homeostasis,
including Th1/Th2 polarization, and tolerance.79,81,95,98,99
Under normal conditions autophagy is involved in the
delivery to and presentation of self-antigens by MHC II,
contributing to the induction and maintenance of CD4þT
cell tolerance.79,83,90 Potentially, enhanced autophagy during
cell stress together with a change in the cytokine milieu may
lead to a weakening or breakdown of tolerance and thereby to
the development of autoimmunity.81,95 In this context, the
description by Kain et al.4 of LAMP2 as a novel autoantigen
in pauci immune vasculitis is of interest. This ‘autoantigen’ is
a major component of chaperone-mediated autophagy for
the delivery of proteins to the autolysosome.77 Kain et al.4
showed that in pauci immune vasculitis LAMP2 becomes an
autoantigen. The authors attribute this to molecular mimicry
with a bacterial antigen. Alternatively, one might speculate
that as both the bacterial antigen and Lamp2 will end up in
the autolysosome during infection, the local control of
tolerance might be overwhelmed in the autolysosome,
resulting in processing not only of the bacterial antigen,
but also of the LAMP2 self-antigen.4 This would then cause
an adaptive immune response not only to the invading
bacteria, but also to the autophagosomal LAMP2. Obviously
this only represents a hypothesis at present.
In B cells autophagy facilitates the interaction of the B-cell
receptor with TLR9 in an autolysosome-like compart-
ment.79,81,95,98,99 This results in enhanced production of
antibodies to DNA antigens, especially in autoimmune
diseases such as systemic lupus.100 The ligand for the TLR9
activation could consist of DNA complexed with HMGBs,
both being released from dying cells.2 Potentially, such
mechanisms could also contribute to an autoimmune
response during progressive tissue damage. For example,
protein and lipid overload of tubular epithelial cells during
proteinuria or prolonged cell stress of epithelial and
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Figure 2 | Schematic illustration of macro-, micro-, and
chaperone-mediated autophagy and the formation of
autolysosomes. Under normal conditions and in the presence of
growth factors, PI3 kinase will be active and stimulate TOR (target
of rapamycin), which will inhibit ATGs and thereby autophagy.
Decreased PI3 kinase activity would result in less TOR activity, less
ATG inhibition, and enhanced autophagy. Rapamycin as an
inhibitor of TOR would also activate ATGs and thereby autophagy.
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endothelial cells due to hypoxia/ischemia and endoplasmic
reticulum stress could enhance the formation of autophago-
somes and autolysosomes, and generation and release of
DAMPs. In adjacent dendritic cells, autolysosomal proteolysis
of DAMPs could potentially generate neoantigens binding to
MHC class I or II molecules for surface presentation and
subsequent T-cell activation.79 This may represent an
intriguing possibility linking cellular protein overload,
endoplasmic reticulum stress, hypoxia, and other mechan-
isms of local cell injury during kidney disease to autophagy
and a resulting autoimmune response as part of progression
of renal diseases. Recently, epitope spreading was identified as
an important factor linking dendritic cell–T cell interaction
during glomerular injury to the subsequent tubulointerstitial
progression of disease.4,28 If, and how, autophagy may
contribute to molecular mimicry of pauci-immune vasculitis,
loss of tolerance, and to epitope spreading in progression of
renal disease should be an area of future research.
SUMMARY AND FUTURE DIRECTIONS
Autophagy is involved in many physiological processes,
ranging from cell metabolism to immune function and
eventually to protection from cell death. As such autophagy is
also involved in the pathophysiology of many diseases. In the
kidney autophagy has been shown to protect against acute
tubular injury and lately to protect glomerular podocytes
from the wear and tear associated with permselective
ultrafiltration.101 As such, autophagy may also be important
as a nonselective bulk protein degradation system, a function
that may be especially pertinent for proteinuric renal disease.
In this context autophagy may deliver filtered as well as
locally generated DAMPs for autolysosomal processing by
tubular epithelial cells, as well as by local dendritic cells and
macrophages. Obviously, this process is similar to the
processing of infectious agents and delivery of PAMPs to
the autolysosomal compartment. During this process DAMPs
and PAMPs interact with TLRs and other receptors of the
innate immune system followed by immune activation, local
inflammation, and acquired immunity. Furthermore, neoan-
tigens, including autoantigens, are generated and presented
to MHC II and I in autophagy-associated compartments,
resulting in loss of tolerance and a full-blown autoimmune
response. Support for these concepts is forthcoming from a
number of experimental immunological studies. In the case
of autoimmune kidney diseases, there exists only some early,
and mostly indirect evidence, for these concepts, which have not
yet been fully tested in kidney diseases. We anticipate that new
studies will examine the role of autophagy not only in acute
tubular and glomerular epithelial injury, but also in chronic
proteinuric and immunological kidney injury. In this context it
may be worthwhile recalling that rapamycin is not only an
immunosuppressive drug, but also an autophagy enhancer.
Potentially, many of the beneficial effects of rapamycin in
experimental kidney disease, and even in patients treated with
rapamycin, may be unrelated to the immune-suppressive effect
of the drug, but may relate to rapamycin activation of
autophagy. Perhaps we have already, but unknowingly, benefited
from the modulation of autophagy by rapamycin therapy. Thus,
research in autophagy and immune-mediated renal disease may
already have started under a different label.
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